New drug shows promise in slowing lung scarring

NCT ID NCT03865927

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested an experimental drug called GKT137831 in 58 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The drug aims to reduce lung damage caused by harmful molecules called reactive oxygen species. Researchers measured changes in blood markers of oxidative stress and collagen breakdown to see if the drug could slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Temple University Medical Center

    Philadelphia, Pennsylvania, 19140, United States

  • Tulane University Medical Center

    New Orleans, Louisiana, 70112, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Michigan Medical Center

    Ann Arbor, Michigan, 48109, United States